CNBX PHARMACEUTICALS INC.: basic weighted-average shares
Basic weighted-average shares for CNBX PHARMACEUTICALS INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All CNBX PHARMACEUTICALS INC. financial histories
What this measure means
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
Exact concept: us-gaap:WeightedAverageNumberOfSharesOutstandingBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-09-01 to 2025-08-31. The SEC response was captured on 2026-09-20.
Reading these values
This selected numerical history matches Diluted weighted-average shares for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.
Context from the filing
CNBX Pharmaceuticals' review covers fiscal years ended August 31, 2024 and 2025, not calendar years. Potentially dilutive shares are excluded as anti-dilutive in both periods. The 2025 statement displays loss EPS as (0.00), alongside a $313,976 net loss and 90,649,474 weighted-average shares; that rounded per-share display does not mean the company had no loss. Dollar amounts and share counts are unscaled. Read the source filing.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-09-01 | 2025-08-31 | 90,649,474 | shares | 2025-12-01 | 10-K · 0001683168-25-008736 |
| 2023-09-01 | 2024-08-31 | 30,247,691 | shares | 2025-12-01 | 10-K · 0001683168-25-008736 |
| 2022-09-01 | 2023-08-31 | 8,824,636 | shares | 2024-11-29 | 10-K · 0001683168-24-008433 |
| 2021-09-01 | 2022-08-31 | 1,222,641 | shares | 2023-11-30 | 10-K · 0001683168-23-008557 |
| 2020-09-01 | 2021-08-31 | 138,519,509 | shares | 2022-11-30 | 10-K · 0001683168-22-008095 |
Related financial histories
- CNBX PHARMACEUTICALS INC.: total assets
- CNBX PHARMACEUTICALS INC.: total liabilities
- CNBX PHARMACEUTICALS INC.: stockholders equity
- CNBX PHARMACEUTICALS INC.: cash and cash equivalents
- CNBX PHARMACEUTICALS INC.: net income or loss
- CNBX PHARMACEUTICALS INC.: operating cash flow
- CNBX PHARMACEUTICALS INC.: revenue
- CNBX PHARMACEUTICALS INC.: financing cash flow
- CNBX PHARMACEUTICALS INC.: investing cash flow
- CNBX PHARMACEUTICALS INC.: retained earnings or deficit
- CNBX PHARMACEUTICALS INC.: diluted weighted-average shares
- CNBX PHARMACEUTICALS INC.: basic earnings per share
- CNBX PHARMACEUTICALS INC.: diluted earnings per share
- CNBX PHARMACEUTICALS INC.: net property, plant and equipment
- CNBX PHARMACEUTICALS INC.: share-based compensation expense
- CNBX PHARMACEUTICALS INC.: operating income or loss
- CNBX PHARMACEUTICALS INC.: current assets
- CNBX PHARMACEUTICALS INC.: interest expense
- CNBX PHARMACEUTICALS INC.: current liabilities
- CNBX PHARMACEUTICALS INC.: operating expenses
- CNBX PHARMACEUTICALS INC.: gross profit
- CNBX PHARMACEUTICALS INC.: research and development expense
Inspect the source
- Entity
- CNBX PHARMACEUTICALS INC. / CIK 0001343009
- Captured
- 2026-09-20T07:54:32.519Z
- SEC response SHA-256
915b78bb9f3d1ecdaff39577a9e5db4b6d0b32a87b795bd1dd92ab6d7b14ac19
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001343009.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))